FDA approves imatinib oral solution to treat leukemia, other cancers
The US Food and Drug Administration (FDA) has approved imatinib (Imkeldi) oral solution to treat leukemia and other cancers. Imatinib is an advanced
The US Food and Drug Administration (FDA) has approved imatinib (Imkeldi) oral solution to treat leukemia and other cancers. Imatinib is an advanced
Pathways & Perspectives Meet Pia Raanani, MD, head of the Institute of Hematology at the Davidoff Cancer Center, Rabin Medical Center in Israel
A new National Cancer Institute (NCI) initiative seeks to redefine the standard for personalized cancer care in acute myeloid leukemia (AML) and myelodysplastic
Wajeeha Aiman, MD, and Muhammad Ashar Ali, MD, discuss the benefits of attending the SOHO Annual Meeting in Houston, Texas, for early-career healthcare
SOHO appoints Sagar Lonial, MD, FACP, of Emory University as Editor-in-Chief to lead the digital and print publication. LOS ANGELES, Jan. 7, 2025 /PRNewswire/ — The Society of Hematologic
In the video interview, Overstijns and Dr. Wijatyk discuss interim results from the phase 2 pivotal Study (DALY II USA) evaluating zamtocabtagene autoleucel
The novel CAR-T demonstrated robust and highly selective eradication of low- and high- mutCALR expressing human cell lines in vitro.
For SOHO, 2024 was a year of firsts and continued growth of the society worldwide.
The Board of Directors and the Steering Committee of the Society of Hematologic Oncology (SOHO) are pleased to announce that Phillip Scheinberg, MD,
Trem-cel enables repeated post-HCT maintenance dosing of gemtuzumab ozogamicin in patients with high-risk AML.